We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-18.21%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.2B
AUM Growth
-$2.97B
Cap. Flow
+$24.4M
Cap. Flow %
0.2%
Top 10 Hldgs %
86.1%
Holding
101
New
4
Increased
12
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$219M
2
AMRN
Amarin Corp
AMRN
+$155M
3
KOD icon
Kodiak Sciences
KOD
+$81M
4
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$22.3M
5
KRYS icon
Krystal Biotech
KRYS
+$14M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$143M
2
SAGE
Sage Therapeutics
SAGE
+$80.2M
3
NVTA
Invitae Corporation
NVTA
+$58.3M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$45.3M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FSTX
51
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$6.37M 0.05%
153,286
– –
ALBO
52
DELISTED
Albireo Pharma Inc
ALBO
$6.13M 0.05%
250,000
– –
CPRX
53
DELISTED
Catalyst Pharmaceutical
CPRX
$5.57M 0.05%
2,900,000
– –
AUTL
54
Autolus Therapeutics
AUTL
$641M
$5.15M 0.04%
156,773
-78,521
-33% -$2.58M
HALO icon
55
Halozyme
HALO
$12.3B
$4.39M 0.04%
299,969
-150,000
-33% -$2.39M
BLUE
56
DELISTED
bluebird bio
BLUE
$3.97M 0.03%
3,088
-1,501
-33% -$2.3M
CRNX icon
57
Crinetics Pharmaceuticals
CRNX
$8.99B
$3.94M 0.03%
131,250
– –
FTSV
58
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$3.93M 0.03%
250,000
– –
XLRN
59
DELISTED
Acceleron Pharma
XLRN
$3.65M 0.03%
83,900
– –
ASMB icon
60
Assembly Biosciences
ASMB
$700M
$3.36M 0.03%
12,382
– –
VKTX icon
61
Viking Therapeutics
VKTX
$3.95B
$3.25M 0.03%
425,000
– –
SYRS
62
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.2M 0.03%
57,484
– –
YARW
63
Yarrow Bioscience
YARW
$97.2M
$2.88M 0.02%
194
– –
GNMX
64
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2.77M 0.02%
3,950,419
– –
SRRA
65
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.64M 0.02%
+50,000
New +$3.19M
APLS
66
DELISTED
Apellis Pharmaceuticals
APLS
$2.59M 0.02%
196,078
– –
GTHX
67
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.44M 0.02%
127,236
– –
LKFT
68
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$2.3M 0.02%
25,072
-212,119
-89% -$21.5M
CCXI
69
DELISTED
ChemoCentryx, Inc.
CCXI
$2.26M 0.02%
207,029
-207,000
-50% -$2.18M
YMAB
70
DELISTED
Y-mAbs Therapeutics
YMAB
$2.09M 0.02%
102,800
-47,200
-31% -$1.08M
ALKS icon
71
Alkermes
ALKS
$8.11B
$1.98M 0.02%
67,000
-33,251
-33% -$1.23M
ORTX
72
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.97M 0.02%
+12,500
New +$1.86M
FOMX
73
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.79M 0.01%
498,189
-189,886
-28% -$826K
NTLA icon
74
Intellia Therapeutics
NTLA
$1.8B
$1.75M 0.01%
128,538
-64,000
-33% -$1.19M
ACHN
75
DELISTED
Achillion Pharmaceuticals
ACHN
$1.74M 0.01%
1,095,359
-544,589
-33% -$1.54M
1 2
3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2018 Portfolio in Review

As of Q4 2018, Julian Baker held 101 positions worth $12.2B, down 20% from $15.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q4 2018 filing shows 4 new, 12 increased, 21 reduced and 10 closed positions. Its largest new stake was Kodiak Sciences: 9,145,115 shares worth $64.9M. The largest sale was Genomic Health, Inc., an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q4 2018 buy was Kodiak Sciences: 9,145,115 shares worth $64.9M.
  • Julian Baker added most to Acadia Pharmaceuticals in Q4 2018, an estimated $219M increase.
  • Julian Baker's biggest Q4 2018 reduction was Genomic Health, Inc., cutting an estimated $143M.
  • Julian Baker fully exited Sage Therapeutics in Q4 2018, selling an estimated $80.2M.
  • Julian Baker's ten largest holdings make up 86% of its $12.2B portfolio in Q4 2018.
  • Julian Baker opened 4 new positions and closed 10 in Q4 2018.
  • Julian Baker's portfolio value fell 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.